bg-rating-rationales

Entity-Specific Rating Rationales

24 Feb 2026

Mankind Pharma Limited: Ratings reaffirmed

Mankind Pharma Limited: Ratings reaffirmed

16 Jan 2026

Mankind Pharma Limited: Rating withdrawn for Rs. 1,500 crore commercial paper programme; ratings outstanding for bank loan facilities and non-convertible debenture programme

Mankind Pharma Limited: Rating withdrawn for Rs. 1,500 crore commercial paper programme; ratings outstanding for bank loan facilities and non-convertible debenture programme

13 Nov 2025

Mankind Pharma Limited: Rating withdrawn for Rs. 3,500 crore commercial paper programme; ratings outstanding for bank loan facilities, non-convertible debenture programme and Rs. 1,500 crore commercial paper programme

Mankind Pharma Limited: Rating withdrawn for Rs. 3,500 crore commercial paper programme; ratings outstanding for bank loan facilities, non-convertible debenture programme and Rs. 1,500 crore commercial paper programme

25 Feb 2025

Mankind Pharma Limited: Long-term rating reaffirmed; short-term rating reaffirmed/ assigned

Mankind Pharma Limited: Long-term rating reaffirmed; short-term rating reaffirmed/ assigned

30 Sep 2024

Mankind Pharma Limited: Ratings reaffirmed for existing non-convertible debentures; ratings assigned for bank loans, commercial papers and non-convertible debentures

Mankind Pharma Limited: Ratings reaffirmed for existing non-convertible debentures; ratings assigned for bank loans, commercial papers and non-convertible debentures

05 Aug 2024

Mankind Pharma Limited - Update on Material Event

Mankind Pharma Limited - Update on Material Event

09 Jul 2024

Mankind Pharma Limited: Rating assigned

Mankind Pharma Limited: Rating assigned

bg-rating-crediet-reports

Entity-Specific Credit Perspective Reports

25 Mar 2026

Mankind Pharma Limited

Mankind Pharma Limited (Non-SF)

26 Mar 2025

Mankind Pharma Limited

Mankind Pharma Limited (Non-SF)

29 Oct 2024

Mankind Pharma Limited

Mankind Pharma Limited (Non-SF)

02 Sep 2024

Mankind Pharma Limited

Mankind Pharma Limited (Non-SF)

Ratings

Description
Short Term
Medium Term
Long Term
Issuer
Long-term/short term fund-based limits [ICRA]A1+ -- [ICRA]AA+(Stable) --
NCD -- -- [ICRA]AA+(Stable) --
Commercial Papers Withdrawn -- -- --

Our Analysts

Analyst 1

Gaurav Kushwaha

Analyst 2

Deepak Jotwani

Sector Head

Jitin Makkar
bg-rating-research

Most Trending Research Reports


View More
bg-rating-rationales

Rating Rationales

icon-download

View More

Credit Quality Trends and ICRA’s Outlook for FY2027

Mr. K Ravichandran,Ms. Aditi Nayar,Mr. Pratik Singhania

01 Apr 2026 04:00 PM
Register now 6 days Left

Road sector hits a slow lane as project awarding moderates

Mr. Suprio Banerjee,Mr. M Rajashekar Reddy

25 Feb 2026 04:00 PM

PPT Icon PPT

Specialty Chemicals: Industry on a slow road to recovery

Girishkumar Kadam,Prashant Vasisht

19 Feb 2026 04:00 PM

PPT Icon PPT

Podcast

View More

Media Release



View More
Ask Our Industry Analyst Get in touch with our Business Representative
Please enter your name
Please enter your mobile number
Please enter your email id
Please enter your company name
Name should not be greater than 50 characters
Please choose sector
Please enter your query
Query to have atleast ten characters
Query should not be greater than 1,000 characters
Please verify you are not a Robot.